Vietnam begins human clinical trial of COVID vaccine ARCT-154
(VOVWORLD) - Hanoi’s Medical University will begin human clinical trials of the ARCT-154 vaccine, the third home-made vaccine against COVID-19, on Sunday (August 15).
 Illustrative photo: VNA |
The study will be conducted in all three phases in Vietnam on volunteers aged 18 years and older. In particular, phase 1 will start this Sunday and Monday with the injection of 1 ARCT-154 vaccine for 100 volunteers.
Earlier, the Ministry of Health approved a proposal on human clinical trials of the ARCT-154 vaccine. The vaccine was purchased with technology transferred to VinBioCare Biotechnology JSC, a unit of Vietnam's leading multisectoral conglomerate Vingroup, from Arcturus Therapeutics Holding Incorporation, USA. This is a vaccine developed on mRNA technology to prevent COVID-19.
VinBioCare has invested in building a vaccine factory in Hoa Lac Hi-Tech Park in Hanoi with total investment capital of more than 200 million USD and a capacity of 200 million doses per year.